Printer Friendly

CYTOTHERAPEUTICS EXPANDS HUMAN TRIAL OF CERECRIB DEVICE IN EUROPE; STUDY TO INCLUDE SURGICAL PROCEDURE WITHIN THE BRAIN

 PROVIDENCE, R.I., Jan. 11 /PRNewswire/ -- CytoTherapeutics, Inc. (NASDAQ: CTII) today announced that patient enrollment for the first human clinical trial of its CereCRIB(TM) implant for severe, chronic pain has been completed. Following successful implantation into the lumbar region of the spinal cord in the initial seven patients specified by the protocol, the study was expanded to include implantation directly into the brain. Initiated in June 1993, the study was designed to determine the safety of implantation and retrieval procedures, as well as the survival of the encapsulated, non-human cells within the implanted devices. The trial has been headed by Patrick Aebischer, M.D., Ph.D., a founding scientist of the company and Professor of Surgery at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland.
 Dr. Aebischer commented, "Implantation directly into the brain allows us to treat intractable pain originating above the mid-chest region. Given our encouraging preliminary observation with implantation into the lumbar region, this approach complements the original protocol for control of pain below the mid-chest region."
 "We expect that the results of Dr. Aebischer's efforts to implant encapsulated cells within specific regions of the brain will be useful in developing and initiating further studies for our programs in Parkinson's, Alzheimer's and Huntington's diseases," said Seth A. Rudnick, M.D., chairman and chief executive officer of CytoTherapeutics.
 Under the original protocol, seven patients received implants in the lumbar region by a common surgical procedure similar to a spinal tap. In the expanded protocol, two patients reporting pain from areas above the mid-chest received implants within the ventricles, or fluid-filled spaces, of theb?rain through a common stereotactic procedure, guided by state-of-the-art medical imaging technology. Following this procedure, both patients were discharged from the hospital within 24 hours. Physicians participating in the trial include: Patrick Aebischer, M.D., Ph.D.; Moses Goddard, M.D., of CytoTherapeutics and associate professor of Surgery at Brown University; and Eric Buchser, M.D., director, Pain Clinic at Morges, Switzerland.
 CytoTherapeutics is a leader in the development of implantable delivery systems for biologically active and gene therapy products for the treatment of central nervous system (CNS) diseases and other chronic disorders. The company's CNS products in development include CereCRIB, for the treatment of severe, chronic pain, and NeuroCRIB(TM), for the treatment of Parkinson's disease. The company is also developing applications of its CRIB(TM) technology for the delivery of growth factors for the treatment of Alzheimer's and Huntington's, as well as other neurodegenerative diseases.
 -0- 1/11/94
 /CONTACT: Seth A. Rudnick, chief executive officer, ext. 2113, or Elizabeth Razee, communications coordinator, ext. 2132, both of CytoTherapeutics, 401-272-3310/
 (CTII)


CO: CytoTherapeutics, Inc. ST: Rhode Island IN: MTC SU:

DJ -- NE001 -- 0841 01/11/94 08:33 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 11, 1994
Words:456
Previous Article:WHITTAKER ELECTRONICS ANNOUNCES $20.4 MILLION NAVY CONTRACT FOR TRIDENT SUBMARINE SUPPORT SYSTEM
Next Article:C-SPAN PICKS UP THE CABLE TELEVISION NETWORK OF NJ'S 'CAPITOL TALK: OUR TAX DOLLARS' LIVE CALL-IN WITH GOVERNOR-ELECT CHRISTIE TODD WHITMAN
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters